使用电子鼻技术检测复发性头颈癌:一项可行性研究
本可行性研究评估电子鼻(e-nose)作为无创诊断工具,在根治性治疗后检测头颈部鳞状细胞癌(HNSCC)局部区域复发和/或第二(或第三)原发肿瘤的诊断性能。使用电子鼻采集20例复发/第二原发肿瘤患者和20例无复发证据患者的呼气样本,基于挥发性有机化合物模式进行人工神经网络分析。结果显示,区分随访患者有无局部区域复发或第二(或第三)原发HNSCC的诊断准确率为83%。
要点
- 电子鼻诊断局部区域复发或第二(或第三)原发HNSCC的准确率为83%。
- 研究纳入20例复发/第二原发肿瘤患者和20例无复发证据患者。
- 基于挥发性有机化合物模式的人工神经网络分析用于区分患者。
核心结论
- 本研究证明使用电子鼻检测局部区域复发和/或第二(或第三)原发HNSCC具有可行性。
研究设计与样本
- 可行性研究,纳入根治性治疗后出现局部区域复发或第二(或第三)原发肿瘤的HNSCC患者20例和无复发证据患者20例,使用电子鼻(Aeonose)采集呼气样本,基于挥发性有机化合物模式进行人工神经网络分析。
主要发现
- 区分随访患者有无局部区域复发或第二(或第三)原发HNSCC的诊断准确率为83%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this feasibility study was to assess the diagnostic performance of an electronic nose (e-nose) as a noninvasive diagnostic tool in detecting locoregional recurrent and/or second (or third) primary head and neck squamous cell carcinoma (HNSCC) after curative treatment. METHODS: Using an e-nose (Aeonose, The eNose Company, Zutphen, The Netherlands), breath samples were collected from patients after curative treatment of an HNSCC with a locoregional recurrence or second (or third) primary tumor (N = 20) and from patients without evidence of recurrent disease (N = 20). Analyses were performed utilizing artificial neural networking based on patterns of volatile organic compounds. RESULTS: A diagnostic accuracy of 83% was observed in differentiating follow-up patients with locoregional recurrent or second (or third) primary HNSCC from those without evidence of disease. CONCLUSION: This study has demonstrated the feasibility of using an e-nose to detect locoregional recurrent and/or second (or third) primary HNSCC.
引用
- van de Goor RMGE, Hardy JCA, van Hooren MRA, et al. Detecting recurrent head and neck cancer using electronic nose technology: A feasibility study. Head Neck. 2019. PMID: 31012533. doi:10.1002/hed.25787
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。